Naltrexone maintenance for heroin dependence: uptake, attrition and retention

Drug and Alcohol Review
Thamizan TuckerHenry Jackson

Abstract

With naltrexone registered only recently in Australia in 1999, it is important to examine the rate of uptake of naltrexone treatment, early attrition and retention rates during treatment, in order to inform the way naltrexone is used in Australian practice. Of 317 people screened for the study, 97 participants were recruited post-withdrawal from opiates and were inducted to naltrexone after a period of at least 5 days of abstinence. While in treatment, participants received a 50-mg dose of naltrexone daily, with daily dispensing for the first 7 days, and weekly dispensing for the following 11 weeks. For the naltrexone-treated sample as a whole, the rate of uptake of naltrexone treatment was 30%, with 30% retained in treatment for the entire 12-week program. Attrition from treatment was found to be steady throughout the 12 weeks. The authors conclude that further research is required to improve withdrawal and naltrexone induction techniques and to improve medication compliance and treatment retention.

References

Aug 1, 1978·The International Journal of the Addictions·D C LewisR Black
Jan 1, 1978·The American Journal of Drug and Alcohol Abuse·S I SideroffM E Jarvik
Apr 1, 1977·Clinical Pharmacology and Therapeutics·R B ResnickD Poole
May 1, 1977·Drug and Alcohol Dependence·L E HollisterP Kasper
Jan 1, 1975·The American Journal of Drug and Alcohol Abuse·C P O'BrienG E Woody
Apr 1, 1989·Drug and Alcohol Dependence·F García-AlonsoJ Cami
Jan 1, 1989·Journal of Substance Abuse Treatment·D H FramR Holden
Jan 1, 1985·Journal of Substance Abuse Treatment·H D Kleber
Feb 1, 1988·British Journal of Addiction·J E Peachey, H Lei
Sep 1, 1986·Journal of Clinical Psychology·T CaponeM Peterson
Jan 1, 1986·Journal of Clinical Psychology·C GreyM Reznikoff
Jan 1, 1980·The American Journal of Drug and Alcohol Abuse·A Schecter
Jan 1, 1984·The American Journal of Drug and Alcohol Abuse·E G SingletonG E Bigelow
Aug 1, 1981·Drug and Alcohol Dependence·L E HollisterH K Gillespie
Jun 15, 1994·Biological Psychiatry·E N ShufmanY Ginath
Jan 1, 1997·Journal of Substance Abuse Treatment·A RothC Farren
Oct 6, 1997·Annals of Internal Medicine·P G O'ConnorB J Rounsaville
Nov 28, 1997·The British Journal of Psychiatry : the Journal of Mental Science·A SeoaneG Sobrepere
Jan 23, 1998·Journal of Substance Abuse Treatment·J W CornishC P O'Brien
Feb 2, 1999·Addiction·H D Kleber
Apr 27, 1999·Drug and Alcohol Dependence·K L PrestonC R Schuster
Mar 24, 2000·European Addiction Research·I IraurgiM Gutiérrez-Fraile
Apr 1, 2000·Journal of Substance Abuse Treatment·R B RothmanJ G Liberto
Oct 6, 2005·Drug and Alcohol Review·A FoyA Taylor

❮ Previous
Next ❯

Citations

May 14, 2008·Expert Opinion on Pharmacotherapy·Francesco Leri
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Jason M White, Olga V Lopatko
Aug 10, 2007·Expert Opinion on Investigational Drugs·Sandra D ComerGary K Hulse
Jun 1, 2012·La Presse médicale·Kamilia KsoudaFlorence Vorspan
Dec 20, 2008·Journal of Biomedical Materials Research. Part a·W O FaridG K Hulse
Dec 20, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hendrik G RoozenAd J F M Kerkhof
Sep 13, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·G K HulseR J Tait
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
Oct 11, 2014·Drug and Alcohol Review·Louisa DegenhardtWayne Hall
Jul 7, 2019·Addiction·Shane DarkeJulia Lappin
Jun 15, 2007·Drug and Alcohol Review·Amy E Gibson, Louisa J Degenhardt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.